Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications |
| |
| Authors: | Hodges B L Evans H K Everett R S Ding E Y Serra D Amalfitano A |
| |
| Affiliation: | Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, NC 27710, USA. |
| |
| Abstract: | The 100K protein has a number of critical roles vital for successful completion of the late phases of the adenovirus (Ad) life cycle. We hypothesized that the introduction of deletions within the 100K gene would allow for the production of a series of new classes of Ad vector, including one that is replication competent but blocked in the ability to carry out many late-phase Ad functions. Such a vector would have potential for several gene therapy applications, based upon its ability to increase the copy number of the transgene encoded by the vector (via genome replication) while decreasing the side effects associated with Ad late gene expression. To efficiently produce 100K-deleted Ad (100K-]Ad) vectors, an E1- and 100K-complementing cell line (K-16) was successfully isolated. Transfection of an E1-,100K-]Ad vector genome into the K-16 cells readily yielded high titers of the vector. After infection of noncomplementing cells, we demonstrated that 100K-]Ad vectors have a significantly decreased ability to express several Ad late genes. Additionally, if the E1 gene was present in the infected noncomplementing cells, 100K-]Ad vectors were capable of replicating their genomes to high copy number, but were significantly blocked in their ability to efficiently encapsidate the replicated genomes. Injection of an E1-,100K-]Ad vector in vivo also correlated with significantly decreased hepatotoxicity, as well as prolonged vector persistence. In summary, the unique properties of 100K-]Ad vectors suggest that they may have utility in a variety of gene therapy applications. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
